Vitamin D enhances efficacy of oral nifedipine in treating preeclampsia with severe features: a double blinded, placebo-controlled and randomized clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013313

Enrollment

Unknown

Registered

2017-11-09

Start date

2011-01-03

Completion date

Unknown

Last updated

2017-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

nifedipine+VD:nifedipine+VD

nifedipine+placebo:nifedipine+placebo

Eligibility

Sex/Gender

Female

Age

31 Years to 37 Years

Inclusion criteria

Inclusion criteria: 1) primigravid women; 2) Gestation age between 20-30 weeks (although expectant management of preeclampsia patients with severe features beyond 34 weeks is accepted in our hospital guideline, it may not be the standard of care in all institutions); 3) hypertensive disorders (=150 mmHg systolic and/or =100 mmHg diastolic); 4) proteinuria (=0.3 g protein/24 hours).

Exclusion criteria

Exclusion criteria: 1) history of heart failure during the course of the pregnancy; 2) history of smoking and/or diabetes, both of which could contribute to hypertension; 3) use of anti-hypertensive drugs and/or VD supplementation; 4) HELLP syndrome or chronic hypertension.

Design outcomes

Primary

Measure	Time frame
time needed to lower blood pressure;time before another hypertensive crisis;	—

Secondary

Measure	Time frame
the number of dosages needed to lower blood pressure;neonatal parameters;serum levels of TNF-a;serum levels of IL-10;	—

Countries

China

Contacts

Public ContactShi Dandan

Cangzhou Central Hospital

wangna19860101@163.com+86 13315703200

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026